The dynamics of relapsed/refractory multiple myeloma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies. LAS VEGAS, Jan. 25, 2024…